NCT04976868 - Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

March 18, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions

Atopic Dermatitis

Interventions

DRUG

Pimecrolimus 1% Top Cream

Elidel® as prescribed within routine clinical practice

Trial Locations (10)

Beijing children's Hospital, Capital Medical University, Beijing

Beijing Hospital, Beijing

Children's Hospital Capital Institute of Pediatrics, Beijing

Peking University First Hospital, Beijing

Peking University Third Hospital, Beijing

Children's hospital of Chongqing medical university, Chongqing

The third affiliated hospital, sun yat-sen university, Guangzhou

The first Hospital of China Medical University, Shenyang

Peking University Shenzhen Hospital, Shenzhen

Tongji Medical College Huazhong University of Science & Technology, Wuhan